How the endocannabinoid system could be a therapeutic target for multiple sclerosis
A review found that cannabinoids and endocannabinoid system modulators promote oligodendrocyte survival and regulate nerve cell signaling, migration, and myelination, offering therapeutic potential for MS beyond symptom relief.
Quick Facts
What This Study Found
Clinical studies confirm cannabinoids relieve MS pain, tremors, and spasticity. Cannabinoids also prevent exaggerated immune responses in the CNS. Both endocannabinoid system modulators and cannabinoid ligands promote oligodendrocyte survival by regulating signaling, migration, and myelination, suggesting potential disease-modifying effects beyond symptom management.
Key Numbers
CB1 and CB2 receptors identified as primary therapeutic targets. Various CB1/CB2 agonists showed anti-inflammatory properties in experimental MS models.
How They Did This
Review focusing on the immunological attack on nerve cells in MS and the role of cannabinoids and the endocannabinoid system in CNS pathology, covering CB1 and CB2 receptor agonists with anti-inflammatory properties.
Why This Research Matters
If cannabinoids can protect oligodendrocytes and promote myelination, they could potentially slow MS progression rather than just manage symptoms. This would represent a fundamental shift in how cannabis is used for MS.
The Bigger Picture
Most current evidence for cannabis in MS focuses on symptom relief. The potential for disease modification through oligodendrocyte protection and remyelination opens an entirely different therapeutic avenue.
What This Study Doesn't Tell Us
Review relies heavily on preclinical data for disease-modifying claims. Clinical evidence limited to symptom management. Mechanism of oligodendrocyte protection not fully established in human studies.
Questions This Raises
- ?Can cannabinoid-based treatments actually promote remyelination in MS patients?
- ?Would earlier cannabinoid intervention in MS course change long-term outcomes?
Trust & Context
- Key Stat:
- Cannabinoids may protect oligodendrocytes and promote myelination
- Evidence Grade:
- Review synthesizing clinical symptom data with preclinical disease-modification evidence.
- Study Age:
- Published in 2022.
- Original Title:
- Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis.
- Published In:
- Molecular biology reports, 49(6), 5117-5131 (2022)
- Authors:
- Khan, Hina, Ghori, Fareeha Khalid, Ghani, Uzma, Javed, Aneela, Zahid, Saadia
- Database ID:
- RTHC-03957
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis do more than just relieve MS symptoms?
This review suggests cannabinoids may protect the cells that produce myelin (oligodendrocytes) and promote nerve cell repair, potentially offering disease-modifying benefits beyond symptom relief.
Which cannabinoid receptors are important for MS?
Both CB1 and CB2 receptors are therapeutic targets. Various agonists of these receptors showed anti-inflammatory properties and promoted oligodendrocyte survival in experimental studies.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03957APA
Khan, Hina; Ghori, Fareeha Khalid; Ghani, Uzma; Javed, Aneela; Zahid, Saadia. (2022). Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis.. Molecular biology reports, 49(6), 5117-5131. https://doi.org/10.1007/s11033-022-07223-5
MLA
Khan, Hina, et al. "Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis.." Molecular biology reports, 2022. https://doi.org/10.1007/s11033-022-07223-5
RethinkTHC
RethinkTHC Research Database. "Cannabinoid and endocannabinoid system: a promising therapeu..." RTHC-03957. Retrieved from https://rethinkthc.com/research/khan-2022-cannabinoid-and-endocannabinoid-system
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.